High estrogen receptor expression in early breast cancer: Chemotherapy needed to improve RFS?

Breast Cancer Research and Treatment

Volumn 128, Issue 1, 2011, Pages 273-281

  Regierer, A C ^a,b   Wolters, R ^a   Kurzeder, C ^c   Wockel A ^c   Novopashenny, I ^a   Possinger, K ^b   Wischnewsky, M B ^a   Kreienberg, R ^c  

^a UNIVERSITY OF BREMEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Adjuvant chemotherapy; Early breast cancer; Endocrine treatment; Estrogen receptor; Immunoreactive score; Quantitative hormone receptor expression

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; METHOTREXATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; TAXOIDS; TREATMENT OUTCOME;

EID: 79959193521     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1334-9     Document Type: Article

References (48)

1. A Goldhirsch JN Ingle RD Gelber, et al. 2009 Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 8 1319 1329 19535820 10.1093/annonc/mdp322 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D
2. F Montemurro M Aglietta 2009 Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy Endocr Relat Cancer 16 4 1091 1102 19726539 10.1677/ERC-09-0033
3. MJ Hassett ME Hughes JC Niland, et al. 2008 Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer J Clin Oncol 26 34 5553 5560 18955448 10.1200/JCO.2008.17.9705
4. B Thürlimann K Price RD Gelber, et al. 2009 Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93 Breast Cancer Res Treat 113 1 137 144 18259856 10.1007/s10549-008-9912-9
5. Pagani O, Gelber S, Simoncini E et al; International Breast Cancer Study Group (2009) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 116(3):491-500
6. G Viale MM Regan E Maiorano, et al. 2008 Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group J Clin Oncol 26 9 1404 1410 18349391 10.1200/JCO.2007.10.6393
7. M Colleoni V Bagnardi N Rotmensz, et al. 2008 Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy Breast Cancer Res Treat 116 2 359 369 18941889 10.1007/s10549-008-0223-y
8. DA Grimes KF Schulz 2002 Bias and causal associations in observational research Lancet 359 248 252 11812579 10.1016/S0140-6736(02)07451-2 (Pubitemid 34113828)
9. CM Booth IF Tannock 2008 Reflections on medical oncology. Twenty-five years of clinical trials in oncology: where have we come and where are we going? J Clin Oncol 26 6 8 18165630 10.1200/JCO.2007.13.8156
10. B Haynes 1999 Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving Br Med J 7211 652 653
11. A Goldhirsch WC Wood RD Gelber, et al. 2007 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 7 1133 1144 17675394 10.1093/annonc/mdm271 1:STN:280:DC%2BD2svlvVSkuw%3D%3D (Pubitemid 47244357)
12. International Breast Cancer Study Group (IBCSG) 2002 Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial J Natl Cancer Inst 94 14 1054 1065
13. International Breast Cancer Study Group M Colleoni S Gelber, et al. 2006 Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93 J Clin Oncol 24 9 1332 1341 16505417 10.1200/JCO.2005.03.0783 1:CAS:528:DC%2BD28Xjs1Ogtrc%3D (Pubitemid 46621995)
14. LF Hutchins SJ Green PM Ravdin, et al. 2005 Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102 J Clin Oncol 23 33 8313 8321 16293862 10.1200/JCO.2005.08.071 1:CAS:528:DC%2BD2MXhtlWhtrjK
15. S Chia W Gradishar 2008 Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer Breast 17 Suppl 3 16 21 10.1016/j.breast.2007.12.004
16. JM Harvey GM Clark CK Osborne, et al. 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 5 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
17. RM Elledge S Green R Pugh, et al. 2000 Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study Int J Cancer 89 2 111 117 10754487 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W 1:CAS:528:DC%2BD3cXislehsrw%3D (Pubitemid 30185917)
18. F Andre K Broglio H Roche, et al. 2008 Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis J Clin Oncol 26 16 2636 2643 18509176 10.1200/JCO.2007.14.9146 1:CAS:528:DC%2BD1cXnvVOhs7c%3D
19. A Reiner J Spona G Reiner, et al. 1986 Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies Am J Pathol 125 443 449 3541638 1:CAS:528:DyaL2sXot1CjsA%3D%3D (Pubitemid 17208829)
20. M Hammond D Hayes M Dowsett, et al. 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 16 2784 2795 20404251 10.1200/JCO.2009.25.6529
21. DC Allred JM Harvey M Berardo, et al. 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 155 168 9504686 1:STN:280:DyaK1c7mtlaitg%3D%3D (Pubitemid 28144151)
22. W Remmele HE Stegner 1987 Vorschlag zur einheitlichen Definierung eines immunreaktiven Scores (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe Pathologe 8 138 140 3303008 1:STN:280:DyaL2s3ovFGhsQ%3D%3D
23. Remmele W (1997) Pathologie Bd 4. Weibliches Genitale; Mamma; Pathologie der Schwangerschaft, der Plazenta und des Neugeborenen; Infektionskrankheiten des Fetus und des Neugeborenen (ed 2). Springer Verlag, Berlin, Heidelberg, New York
24. G Viale MM Regan E Maiorano, et al. 2007 Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 25 25 3846 3852 17679725 10.1200/JCO.2007.11.9453 (Pubitemid 47477259)
25. M Dowsett C Allred J Knox, et al. 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial J Clin Oncol 26 7 1059 1065 18227529 10.1200/JCO.2007.12. 9437 1:CAS:528:DC%2BD1cXktVKisbg%3D
26. Paik S, Shak S, Tang G, et al (2005) Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 23(16S); (Suppl, Abstr 510)
27. Fisher B, Jeong JH, Bryant J et al; National Surgical Adjuvant Breast and Bowel Project Randomised Clinical Trials (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364(9437):858-868
28. C Mazouni P Bonnier A Goubar, et al. 2010 Is quantitative oestrogen receptor expression useful in the evaluation of the clinical prognosis? Analysis of a homogeneous series of 797 patients with prospective determination of the ER status using simultaneous EIA and IHC Eur J Cancer 46 2715 2716 10.1016/j.ejca.2010.05.021
29. KL Henriksen BB Rasmussen AE Lykkesfeldt, et al. 2009 An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer Acta Oncol 48 4 522 531 19173092 10.1080/02841860802676383 1:CAS:528:DC%2BD1MXkvFCiuro%3D
30. M De Laurentiis G Cancello D D'Agostino, et al. 2008 Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 1 44 53 18165639 10.1200/JCO.2007.11.3787
31. PL Bedard A Di Leo MJ Piccart-Gebhart 2010 Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer Nat Rev Clin Oncol 7 22 36 19997076 10.1038/nrclinonc.2009.186 1:CAS:528:DC%2BD1MXhs1SqsLfL
32. DA Berry C Cirrincione IC Henderson ML Citron, et al. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer J Am Med Assoc 295 14 1658 1667 10.1001/jama.295.14. 1658 1:CAS:528:DC%2BD28XjsVeqs7k%3D
33. MC Green AU Buzdar T Smith, et al. 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992 16087943 10.1200/JCO.2005.06.232 1:CAS:528:DC%2BD2MXhtVKgtb3O
34. C Mazouni SW Kau D Frye, et al. 2007 Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers Ann Oncol 18 874 880 17293601 10.1093/annonc/mdm008 1:STN:280:DC%2BD2s3ns1Kmsg%3D%3D (Pubitemid 47054084)
35. von Minckwitz G, Blohmer JU, Raab G et al; German Breast Group (2005) In vivo chemosensitivity adapted preoperative chemotherapy in patients with early-stage breast cancer-the GEPARTRIO pilot study. Ann Oncol 16:56-63
36. C Sotiriou L Pusztai 2009 Gene-expression signatures in breast cancer N Engl J Med 360 8 790 800 19228622 10.1056/NEJMra0801289 1:CAS:528: DC%2BD1MXitFWqs70%3D
37. L Pusztai 2006 Chips to bedside: incorporation of microarray data into clinical practice Clin Cancer Res 12 24 7209 7214 17189391 10.1158/1078-0432. CCR-06-2649 1:CAS:528:DC%2BD28XhtlCrsbfK (Pubitemid 46095390)
38. S Mook MK Schmidt G Viale, et al. 2009 The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study Breast Cancer Res Treat 116 2 295 302 18661261 10.1007/s10549-008-0130-2 1:CAS:528:DC%2BD1MXntF2ntrw%3D
39. JM Bueno-de-Mesquita SC Linn R Keijzer, et al. 2009 Validation of 70-gene prognosis signature in node-negative breast cancer Breast Cancer Res Treat 117 3 483 495 18819002 10.1007/s10549-008-0191-2 1:STN:280:DC%2BD1MnislWmtQ%3D%3D
40. S Paik S Shak G Tang, et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 27 2817 2826 15591335 10.1056/NEJMoa041588 1:CAS:528:DC%2BD2MXhslymsw%3D%3D (Pubitemid 40051905)
41. S Paik G Tang S Shak, et al. 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 23 3726 3734 16720680 10.1200/JCO.2005.04.7985 1:CAS:528:DC%2BD28XpsVaqsrs%3D (Pubitemid 46622311)
42. Albain KS, Barlow WE, Shak S et al; Breast Cancer Intergroup of North America (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55-65
43. LJ Goldstein R Gray S Badve, et al. 2008 Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features J Clin Oncol 26 25 4063 4071 18678838 10.1200/JCO.2007.14.4501
44. M Knauer S Mook EJ Rutgers, et al. 2010 The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer Breast Cancer Res Treat 120 3 655 661 20204499 10.1007/s10549-010-0814-2 1:CAS:528: DC%2BC3cXjs1ajtbc%3D
45. Tang G, Cuzick J, Wale C, et al (2010) Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: a meta-analysis approach. J Clin Oncol 28:15s; (suppl, abstr 509)
46. W Hauck S Anderson S Marcus 1998 Should we adjust for covariates in nonlinear regression analyses of randomized trials? Control Clin Trials 19 3 249 256 9620808 10.1016/S0197-2456(97)00147-5 1:STN:280:DyaK1c3ot1Wgsg%3D%3D (Pubitemid 28255120)
47. ML Berger M Mamdani D Atkins, et al. 2009 Good research practices for comparative effectiveness research: defining, reporting and interpreting non-randomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report-Part I Value Health 12 8 1044 1052 19793072 10.1111/j.1524-4733.2009. 00600.x
48. E Cox BC Martin T Van Staa, et al. 2009 Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of non-randomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force-Part II Value Health 12 8 1053 1061 19744292 10.1111/j.1524-4733.2009.00601.x